NPI 1295739902: Open Payments
NPI 1295739902. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$213 in 10 payments from 8 companies in 2025. Trend: 2023 $282 · 2024 $161 · 2025 $213
Food & beverage: $213
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $62 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Lundbeck LLC | 1 | $25 |
| PFIZER INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| Amgen Inc. | 1 | $14 |
| ABBVIE INC. | 1 | $14 |
Products named: FANAPT, RECORLEV, REXULTI, NURTEC ODT, FARXIGA, CAPLYTA, OTEZLA, VRAYLAR.
